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ABSTRACTS
Malignancies, prothrombotic mutations, and the risk of venous
thrombosis
Blom JW, Doggen CJM, Osanto S, et al. JAMA 2005;293:715-22.
Conclusion:There is an increased risk of venous thrombosis in patients
with cancer. The risk is greatest in the first few months after diagnosis and in
the presence of distal metastasis. Patients also with Factor V Leiden and
prothrombin 20210A mutations have even higher risk.
Summary: This is a report of the Multiple Environmental and Genetic
Assessment (MEGA) of Risk Factors for Venous Thrombosis Study. MEGA
is a case controlled population based study evaluating risk of venous throm-
bosis with various risk factors. This report details risk of venous thrombosis
with cancer and the joint effects of cancer and selected genetic mutations
predisposing to venous thrombosis. Patients were identified at 6 anticoagu-
lation clinics in the Netherlands betweenMarch 1, 1999, andMay 31, 2002.
Patients included were those 18-70 years of age with a first time diagnosis of
pulmonary embolism or lower extremity deep venous thrombosis. Control
patients, (partners of the patients with venous thrombosis) were also utilized
in the study. Both patients and controls received a questionnaire to evaluate
acquired risk factors for venous thrombosis. Once anticoagulation therapy
had been discontinued for three months, patients and controls were inter-
viewed and blood taken for analysis of Factor V Leiden and prothrombin
20210A mutations.
In patients with malignancy, the overall risk of venous thrombosis was
increased 7 times (odds ratio [OR], 6.7; 95% CI, 5.2-8.6). The highest risk
was present in patients with hematologic malignancies (OR 28.0, 95% CI,
4.0-199.7). Risk was also substantially increased in patient with gastrointes-
tinal cancers (OR 18.9; 95% CI, 4.6-77.8), and patients with pulmonary
malignancies (OR 24.8; 95% CI, 3.4-181.1). Risk was highest in the first
several months following malignancy diagnosis (adjusted OR 53.5; 95% CI,
8.6-334.3). In patients with cancer the presence of distal metastatic disease
further increased the risk of venous thromboembolism (VTE) compared to
patients without metastatic disease (adjusted OR, 19.8; 95% CI, 2.6-149.1).
The combination of cancer and Factor V Leiden mutation increased the risk
of VTE 12 times compared to patients with Factor V Leiden mutation and
no diagnosed malignancy. Results were similar for patients with and without
cancer with respect to the prothrombin 20210A mutation.
Comment: The data raises the question as to whether patients with
cancer should be screened for Factor V Leiden and prothrombin 20210A
mutation and treated with prophylactic anticoagulation therapy if a muta-
tion is present. Also the question arises whether prophylactic anticoagulation
is indicated in patients with malignancies associated with an especially high
risk for VTE. The cost effectiveness of such strategies and the ultimate ability
of such strategies to prolong life or improve quality of life are clear in patients
with cancer who are undergoing surgery or active chemotherapy (ACTA
Haematol 2001;106:73-80). There is currently no data to suggest routine
prophylaxis for VTE in all cancer patients would be effective. However, the
results of the current study suggest certain subgroups of patients with cancer
should be studied more closely for potential benefit of routine VTE prophy-
laxis.
Perioperative beta-blocker therapy and mortality after major non
cardiac surgery
Lindenauer PK, Pekow P, Wang K, et al. N Engl J Med 2005; 353:349-61.
Conclusion: Perioperative beta-blocker therapy reduces risks of in-
hospital death in high-risk patients undergoing major non-cardiac surgery.
Summary: The authors conducted a retrospective cohort study of
patients18 years of age undergoing major non-cardiac surgery in the years
2000 and 2001 in 329 hospitals in the United States. The aim was to assess
the use of perioperative beta blockers and their effects on in-hospital
mortality as used in routine clinical practice. Propensity scoring matching
was used to adjust for differences in patients who received and who did not
receive perioperative beta blockers. In-hospital mortality was compared
using multivariable logistic modeling. Surgical procedures were categorized
using available DRG software. The procedure was considered major if the
median length of stay by diagnostic group exceeded two days. Information
was recorded regarding age, sex, race, ischemic heart disease, congestive
heart failure, cerebrovascular disease, renal insufficiency, diabetes, hyperlip-
idemia and hypertension. Other perioperative medications such as angioin-
tensin converting enzyme inhibitors, calcium channel blockers, and anti-
platelet agents and methods of venous prophylaxis were also recorded.
Contraindications to beta blocker therapy were assessed.
There were 782,969 patients analyzed; 85% apparently had no contra-
indication to beta blockers. 18% (n  122,338) received beta blocker
therapy in the first two hospital days. Fourteen percent of patients had a
revised cardiac risk index (RCRI) score of 0 and 44% had a score of 4 or
higher. Risk of death related to perioperative beta-blocker treatment varied
directly with cardiac risk. In 580,665 patients with a RCRI score of 0 or 1
there was no benefit from perioperative beta-blockers. Among patients with
a RCRI score of 2, 3, or 4, adjusted odds ratio for death in the hospital were
0.88 (95% CI, 0.8 to 0.98), 0.71 (95% CI, 0.63 to 0.80), and 0.58 (95% CI,
0.50 to 0.67), respectively.
Comment:Only approximately 51,000 of the patients analyzed in this
study underwent a vascular surgical procedure. Nevertheless, vascular pa-
tients generally have increased cardiac risk and the results of this study
support strongly the use of beta blockers in patients with high cardiac risk.
There is no question that the perioperative use of beta-blockers as a routine
in vascular surgical patients without contraindications to beta blocker ther-
apy should be standard practice.
Carotid plaque pathology: Thrombosis, ulceration, and stroke
pathogenesis
Fisher M, Paganini-Hill A, Martin A, et. al. Stroke 2005;36:253-57.
Conclusion: Carotid plaque ulceration and thrombus are more prev-
alent in symptomatic patients.
Summary: This was a microscopic analysis of carotid plaques surgically
removed from patients enrolled in the North American Symptomatic Ca-
rotid Endarterectomy Trial (NASCET), and in the Asymptomatic Carotid
Atherosclerosis Study (ACAS). Microscopic plaque morphology was com-
pared in patients with and without stroke symptoms ipsilateral and contralat-
eral to the plaque. The presence of calcification, thrombus, and ulceration
were used to characterize the plaques. There were a total of 241 subjects
from whom plaques were obtained with 128 subjects having no history of
stroke symptoms, 80 subjects with symptoms ipsilateral to the plaque and 33
with symptoms contralateral to the plaque. Of the subjects, 170 had been
enrolled in ACAS and 71 in NASCET.
Ulceration of the plaque was more common when the plaque was
removed from a symptomatic patient than when the plaque was obtained
from an asymptomatic patient (36% versus 14%; P 0.001). The frequency
of ulceration was similar in plaques associated with ipsilateral (34%) and
contralateral symptoms (42%). Thrombus was more common in plaques
removed from patients with both ipsilateral symptoms and ulceration.
Calcification was not associated with stroke symptoms.
Comment: This is another indirect attempt trying to determine which
plaques in asymptomatic patients may have a greater propensity to produce
stroke. The authors conclusions are not new, not unexpected, and add very
little to what is already known or suspected. There continues to be great
interest in characterizing surgically removed plaques. What is needed is a
preoperative marker of plaque virulence that is sufficiently sensitive and
powerful to improve selection of patients with asymptomatic carotid stenosis
for a prophylactic carotid intervention.
Soluble CD40L and cardiovascular risk in asymptomatic low-grade
carotid stenosis
Novo S, Basili S, Tantillo R, et al. Stroke 2005;36:673-75.
Conclusion: High levels of soluble CD40L are associated with an
increased risk of cardiovascular events in patients with asymptomatic mini-
mal carotid stenosis.
Summary: C-reactive protein, IL-6, and CD40L have all been shown
in prospective studies to predict the risk of development of cardiovascular
disease. In addition, soluble CD40L (sCD40L) has been shown to be
associated with features of high-risk plaques. This investigation focused on
whether sCD40L can predict risk of cardiovascular events in patients who
have known minimal asymptomatic carotid plaques.
The authors studied 42 patients with asymptomatic low-grade carotid
stenosis and 21 control patients without evidence of carotid stenosis. All
patients had at least onemajor cardiovascular risk factor.Measurements were
made of C-reactive protein (CRP), IL-6, and sCD40L. Subjects were
followed up every 12 months with a median follow up of 8 years. No patient
was lost to follow up.
There were 14 patients (33%), who experienced a vascular event (4 non
fatal myocardial infarctions, 2 strokes and 4 transient ischemic attacks). In
addition, 2 patients developed intermittent claudication and 2 had a need for
a percutaneous revascularization procedure. Patients with cardiovascular
events had higher median values of sCD40L (9.1 versus 5.6 ng/mL;
P 0.02), than those who did not have a cardiovascular event. Overall, the
patients with minimal asymptomatic carotid plaquing had higher CRP, IL-6
and sCD40 levels than controls (P  0.0001). Cox regression analysis
indicated only sCD40L levels (P 0.003), were independently predictive of
cardiovascular risk.
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